Descripción del proyecto
Unos organoides pancreáticos podrían acelerar el desarrollo de un tratamiento eficaz para el cáncer de páncreas
Si bien el cáncer de páncreas es el onceavo cáncer más común en todo el mundo, es la séptima principal causa de las muertes relacionadas con el cáncer. A pesar de los avances en su diagnóstico y gestión, la tasa de supervivencia a cinco años sigue siendo inferior al 10 %. La red de formación PRECODE está aprovechando una técnica recién desarrollada, el autoensamblaje de tejidos funcionales que imitan a órganos, para acelerar el desarrollo de medicamentos para esta enfermedad letal. Unos jóvenes investigadores están perfeccionando sus capacidades de cultivo y manipulación de organoides pancreáticos para comprender mejor el avance de la enfermedad. En última instancia, el uso de organoides pancreáticos creados a partir de las células del paciente podría dar lugar a una medicina personalizada selectiva, específica y extremadamente eficaz contra el cáncer de páncreas.
Objetivo
The PRECODE Network (PancREatic Cancer OrganoiDs rEsearch) central mission is to establish pancreatic organoid research firmly in the European Union, by training the next generation of creative and innovative researchers in pancreatic cancer. This will be done through a shared doctorate program of excellence that fulfils the three “I”: international, interdisciplinary and intersectorial. Organoids can be viewed as small micro-organs which can recapitulate the organization and the function thereof. As micro-organs organoids can be used to reduce animal experiments and help to reach 3R goals. Organoids from pancreatic cancer will help us to learn which drugs might help in the therapy of this terrible disease. They can be isolated from a variety of clinical sources with minimal material needed. This makes them a perfect tool for precision medicine. Sequencing, metabolomics and high throughput in vitro experiments to deduct the best possible drug combination fit hand in glove with this approach. Training of ESRs will be achieved by e-learning, workshops and secondments. They will earn to cultivate and manipulate organoids as well as cutting edge molecular biology techniques. Therefore our work group consists of 15 beneficiaries and 7 partner organization (including three patient advocate groups from Sweden, Italy and Germany) to develop those technologies and to train ESRs in their application. PRECODE will therefore connect the concepts of investigation, education and innovation establishing a capacitation for the ESRs that goes beyond the state of the art and that will allow them to improve their competences and their professional career at the same time that we advance towards innovation in the field of pancreatic cancer research.
Ámbito científico
Palabras clave
Programa(s)
Régimen de financiación
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinador
91054 Erlangen
Alemania